LNA SANTÉ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.5 EUR | +1.99% |
|
+0.99% | +1.99% |
| May. 02 | LNA Santé: 4.9% increase in quarterly sales | CF |
| Mar. 28 | LNA Santé: 9% drop in annual RNPG | CF |
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company does not generate enough profits, which is an alarming weak point.
- One of the major weak points of the company is its financial situation.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +1.99% | 226M | C+ | ||
| +16.17% | 82.36B | C+ | ||
| -29.41% | 69.97B | B- | ||
| +10.99% | 29.41B | C+ | ||
| -11.35% | 16.99B | B | ||
| +0.21% | 17.08B | A- | ||
| -0.68% | 15.21B | A- | ||
| -1.40% | 11.84B | A- | ||
| +3.44% | 13.25B | B- | ||
| +31.43% | 12.08B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LNA Stock
- Ratings LNA Santé